神戸大学附属図書館デジタルアーカイブ
入力補助
English
カテゴリ
学内刊行物
ランキング
アクセスランキング
ダウンロードランキング
https://hdl.handle.net/20.500.14094/0100482050
このアイテムのアクセス数:
295
件
(
2024-07-03
14:54 集計
)
閲覧可能ファイル
ファイル
フォーマット
サイズ
閲覧回数
説明
0100482050 (fulltext)
pdf
514 KB
282
メタデータ
ファイル出力
メタデータID
0100482050
アクセス権
open access
出版タイプ
Accepted Manuscript
タイトル
Systemic Opioids for Dyspnea in Cancer Patients: A Real-world Observational Study
著者
Yamaguchi, Takashi ; Matsunuma, Ryo ; Matsuda, Yoshinobu ; Tasaki, Junichi ; Ikari, Tomoo ; Miwa, Satoru ; Aiki, Sayo ; Takagi, Yusuke ; Kiuchi, Daisuke ; Suzuki, Kozue ; Oyamada, Shunsuke ; Ariyoshi, Keisuke ; Kihara, Kota ; Mori, Masanori
著者ID
A1495
研究者ID
1000010725394
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=34000224acf4b046520e17560c007669
著者名
Yamaguchi, Takashi
山口, 崇
ヤマグチ, タカシ
所属機関名
医学部附属病院
著者ID
A2534
著者名
Matsunuma, Ryo
松沼, 亮
マツヌマ, リョウ
所属機関名
医学部附属病院
著者名
Matsuda, Yoshinobu
著者名
Tasaki, Junichi
著者名
Ikari, Tomoo
著者名
Miwa, Satoru
著者名
Aiki, Sayo
著者名
Takagi, Yusuke
著者名
Kiuchi, Daisuke
著者名
Suzuki, Kozue
著者名
Oyamada, Shunsuke
著者名
Ariyoshi, Keisuke
著者名
Kihara, Kota
著者名
Mori, Masanori
収録物名
Journal of Pain and Symptom Management
巻(号)
65(5)
ページ
400-408
出版者
Elsevier
刊行日
2023-05
公開日
2024-05-01
抄録
Context: Although Systemic opioids are recommended as a pharmacological treatment for cancer-related dyspnea, their effectiveness and safety needs to be investigated in a real-world context. Objectives: To evaluate the effectiveness and safety of systemic regular opioids for dyspnea in cancer patients, in the real-world palliative care practice. Methods: This was a multicenter prospective observational study. We consecutively enrolled adult cancer patients starting regular opioids (morphine, oxycodone, hydromorphone, or fentanyl) for dyspnea from 12 palliative care services across Japan. We evaluated dyspnea intensity using the Numerical Rating Scale (NRS) and Integrated Palliative Outcome Scale (IPOS) every 24 hours until 72 hours after starting opioids (T1–T3). We also evaluated common opioid-related adverse events (AEs) and other severe AEs. Results: We enrolled 402 cancer patients. The proportion of responders was 68.8% (95%confidence intervals (CI): 0.63–0.74) at T1, 75.7% (95%CI: 0.70–0.81) at T2, and 82.1% (95%CI: 0.76–0.87) at T3. The mean differences in dyspnea NRS from baseline were 1.73 (95%CI: 1.46–1.99) at T1, 1.99 (95%CI: 1.71–2.28) at T2, and 2.47 (95%CI:2.13–2.82) at T3. The most common treatment-emergent AE was somnolence with an incidence of the severe form of approximately 10% throughout the study period. In the multivariate analysis, baseline dyspnea NRS ≥6 had a positive correlation with dyspnea relief by systemic regular opioids, while liver metastasis, clinician-predicted survival days, and opioid tolerance had a negative correlation. Conclusion: Regular systemic opioids were effective for dyspnea in real-world cancer patients.
キーワード
Dyspnea
cancer
opioid
palliative care
real-world
カテゴリ
医学部附属病院
学術雑誌論文
権利
© 2023 Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine.
This manuscript version is made available under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license.
詳細を表示
資源タイプ
journal article
言語
English (英語)
ISSN
0885-3924
OPACで所蔵を検索
CiNiiで学外所蔵を検索
eISSN
1873-6513
OPACで所蔵を検索
CiNiiで学外所蔵を検索
関連情報
DOI
https://doi.org/10.1016/j.jpainsymman.2022.12.146
ホームへ戻る